Inflammation: Clinical Trials

145 trials for Inflammation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

145 unknown. 145 Phase 2, 30 Phase 3, 27 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2145Unknown 145
Phase 330Unknown 30
Phase 127Unknown 27

Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation

Trials (filtered) newest first · largest first

All 145 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Comparative Study Between Dexmedetomidine Versus Methylprednisolone on Induced Inflammatory Response in Patients Undergoing On-pump CABG
Normal saline, Dexmedetomidine, Methylprednisolone - Coronary Artery Disease, Systemic Inflammatory Response Syndrome
Phase 1 / Phase 2UnknownAin Shams University602025-09-012025-08-06
Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis
Imatinib, Compound sodium lactate solution - Sepsis, Fluid Overload
Phase 1 / Phase 2UnknownBelfast Health and Social Care Trust652024-12-012024-10-04
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
MRG-001 (Low-dose), MRG-001 (High-dose), Placebo - Acute Respiratory Distress Syndrome, Respiratory Failure
Phase 2UnknownMedRegen LLC602024-12-012024-08-23
Cilostazol in Parkinson's Disease
Cilostazol, Placebo, Standard treatment - Parkinson's Disease
Phase 2UnknownAin Shams University502024-10-012024-09-25
Black Seed Oil in ADHD
Atomoxetine, Black Seed Oil Cap/Tab - ADHD
Phase 2UnknownAin Shams University602024-10-012024-08-09
Beta-Hydroxybutyrate Feasibility Treating IBD
Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's - Crohn's Disease, Inflammatory Bowel Diseases
Phase 1 / Phase 2UnknownUniversity of Texas at Austin202024-08-282024-09-19
Early Resuscitation in Paediatric Sepsis Using Inotropes
Fluid, Adrenalin - Sepsis
Phase 2UnknownNATALIA LOPERA MUNERA402024-07-012024-06-27
Dexmedetomidine and Vasopressin in Septic Shock
DEX-PRESSIN, Standard of Care - Sepsis, Septic Shock
Phase 2UnknownMansoura University2602024-06-012024-03-12
Role of Active Deresuscitation After Resuscitation:
Furosemide Injection, Metolazone Tablets - Fluid Overload, Critical Illness
Phase 2UnknownUnity Health Toronto1202024-05-012024-03-22
Metformin and Lactoferrin in Sepsis in Icu
Metformin, Lactoferrin - Sepsis
Phase 2 / Phase 3UnknownTanta University602024-04-012024-04-19
Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Colchicine, Placebo - Heart Failure With Preserved Ejection Fraction, Microvascular Coronary Artery Disease
Phase 2 / Phase 3UnknownMontreal Heart Institute602024-03-012024-01-25
Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.
Dobutamine - Sepsis, Hypoperfusion
Phase 2UnknownFederal University of São Paulo1202024-02-012024-01-30
The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)
Colchicine, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2UnknownTor Biering-Sørensen1522024-01-182024-02-28
Effectiveness of Asiaticoside as Intracanal Medication on Infectious/Inflammatory Contents in Teeth With Apical Periodontitis
Calcium Hydroxide Intracanal medication, Leddermix Intracanal medication, Asiaticoside Intracanal medication - Intracanal Medication
Phase 2 / Phase 3UnknownMansoura University362023-11-202024-08-22
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
STC314 Injection/STC314 Injection Placebo - Sepsis
Phase 2UnknownGrand Medical Pty Ltd.1802023-11-202024-08-12
Early Versus Conventional Cessation of Hydrocortisone in Septic Shock
normal saline solution, Hydrocortisone and normal saline solution - Septic Shock, Adverse Event
Phase 2UnknownMahidol University1602023-07-052024-04-05
Beta-glucans for Hospitalised Patients With COVID-19
MC 3x3, Placebo - COVID-19
Phase 2UnknownWohlstand Pharmaceutical602023-06-012022-12-13
Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF)
Dexamethasone, Prednisone - Acute Heart Failure
Phase 2 / Phase 3UnknownAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1202023-04-242023-12-04
Alpha-Lipoic Acid in Patients With Sepsis
Alpha-Lipoic Acid, Sepsis Supportive Care - Sepsis
Phase 2 / Phase 3UnknownAin Shams University602023-03-102023-04-12
Dexmedetomidine and HIPEC
Dexmedetomidine, Placebos - Inflammation, Cancer
Phase 2 / Phase 3UnknownUniversity of British Columbia202023-03-012022-11-03

Showing 20 of 145. Sign in to see all of them.

Narrower conditions

Sepsis (42)  ·  Shock, Septic (26)  ·  COVID-19 (13)  ·  Cytokine Release Syndrome (12)  ·  Atherosclerosis (6)  ·  Insulin Resistance (6)  ·  Systemic Inflammatory Response Syndrome (6)  ·  Neuroinflammatory Diseases (5)  ·  Respiratory Distress Syndrome (5)  ·  Shock (5)  ·  Bacteremia (4)  ·  Diabetes Mellitus (4)  ·  Diabetes Mellitus, Type 2 (4)  ·  Acute Kidney Injury (3)

Broader conditions

Pathological Conditions, Signs and Symptoms (145)  ·  Pathologic Processes (143)  ·  Infections (75)  ·  Systemic Inflammatory Response Syndrome (69)  ·  Shock (39)  ·  Respiratory Tract Diseases (26)  ·  Lung Diseases (25)  ·  Cardiovascular Diseases (20)  ·  Vascular Diseases (19)  ·  Sepsis (18)  ·  Nutritional and Metabolic Diseases (17)  ·  RNA Virus Infections (16)  ·  Respiratory Tract Infections (16)  ·  Nervous System Diseases (15)

Interventions

Saline Solution (6)  ·  esmolol (4)  ·  Colchicine (3)  ·  Docosahexaenoic Acids (3)  ·  Terlipressin (3)  ·  Angiotensin II (2)  ·  Ascorbic Acid (2)  ·  Control Groups (2)  ·  Dexamethasone (2)  ·  Dexmedetomidine (2)  ·  Dobutamine (2)  ·  Hydrocortisone (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  Lactoferrin (2)  ·  Meropenem (2)

Sponsors

Ain Shams University (6)  ·  University of British Columbia (4)  ·  University of Sao Paulo General Hospital (4)  ·  Mahidol University (3)  ·  Azienda Ospedaliera di Padova (2)  ·  Dascena (2)  ·  Fast Forward Pharmaceuticals (2)  ·  Leiden University Medical Center (2)  ·  Mansoura University (2)  ·  Oslo University Hospital (2)  ·  Radboud University Medical Center (2)  ·  101 Therapeutics (1)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Assaf-Harofeh Medical Center (1)  ·  Assistance Publique - Hôpitaux de Paris (1)

Countries

United States (20)  ·  China (14)  ·  Brazil (10)  ·  Egypt (9)  ·  Canada (8)  ·  Netherlands (7)  ·  Italy (6)  ·  Mexico (5)  ·  Indonesia (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  France (3)  ·  Germany (3)  ·  Iran (3)  ·  Israel (3)

Top investigators

Agung Putra, Assoc.Prof (1)  ·  Alaa Hemida (1)  ·  Alejandra Correa, MD (1)  ·  Alexander J Clark, MD, FRCPC (1)  ·  Alfredo R Zarate, MD (1)  ·  Amalia Pinguello, MD (1)  ·  Amany Bader, prof (1)  ·  Antoine Kimmoun, MD (1)  ·  Arash Shirvani, MD, PhD (1)  ·  Bambang Darwono, Dr.Sp.OT (1)  ·  Beata Banaszewska (1)  ·  Bianca Gutfilen, PhD (1)  ·  Bruno Levy, MD PhD (1)

Results publications

PMID 10415784, PMID 11402097, PMID 12563677, PMID 12628952, PMID 1342820, PMID 14719037, PMID 15030944, PMID 15234492, PMID 15663512, PMID 16164444, PMID 17181919, PMID 17662768, PMID 18003941, PMID 18097874, PMID 18289548, PMID 18289791, PMID 18546285, PMID 19056593, PMID 19105791, PMID 19397687, PMID 19453649, PMID 19998041, PMID 20084502, PMID 20920189, PMID 21131395, PMID 21187189, PMID 21458008, PMID 21638157, PMID 22028728, PMID 22465313, PMID 22545014, PMID 22666356, PMID 22731679, PMID 22985725, PMID 23327349, PMID 23509945, PMID 23562296, PMID 23612995, PMID 23782971, PMID 24641437, PMID 24675228, PMID 25104975, PMID 25378457, PMID 25469528, PMID 25511715, PMID 25634565, PMID 25986785, PMID 26431839, PMID 26545141, PMID 26866499

NIH funding

2015 (2), 2008 (1), 2014 (1), 2018 (1), K08HD052885 (1), R01HD068712 (1), R33AT009991 (1), R44AA030000 (1), R44DK059062 (1)